Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | BRD2 | P25440 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59156 | 0.98 | — | — | |
| SCHEMBL1980634 | 0.95 | BRD4 (0.44) | BRD4BRD2LMNAPIK3CDMEN1 | |
| SCHEMBL15064811 | 0.95 | BRD4 (0.39) | BRD4BRD2LMNAPIK3CDMEN1 | |
| Ammonia Solution, Strong SCHEMBL11574327 | 0.95 | BRD4 (0.39) | BRD4BRD2LMNAPIK3CDMEN1 | |
| SCHEMBL3666581 | 0.95 | BRD4 (0.39) | BRD4BRD2LMNAPIK3CDMEN1 | |
| SCHEMBL565144 | 0.95 | BRD4 (0.39) | BRD4BRD2LMNAPIK3CDMEN1 | |
| SCHEMBL9564656 | 0.83 | — | — | |
| SCHEMBL622497 | 0.79 | — | — | |
| SCHEMBL2930849 | 0.75 | BRD4 (0.46) | BRD4BRD2LMNAPIK3CDMEN1 | |
| SCHEMBL6122067 | 0.75 | BRD4 (0.46) | BRD4BRD2LMNAPIK3CDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1573 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106917-A1 | EDIBLE TRANSMUCOSAL DRUG DELIVERY METHOD USING AN INTERMEDIATE CAPSULE AS A TEMPORARY VESSEL | BioPhysics Pharma, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| WO-2026104612-A1 | FORMULATION COMPRISING UREA | DIOMED DEVELOPMENTS LIMITED (GB) | 2026-05-21 | — | — | WO | claimed |
| EP-4731683-A1 | RECOMBINANT CELL WALL HYDROLASES | Topaz Biosciences, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-12605328-B2 | Cosmetic compositions and methods | MARY KAY INC. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4719336-A1 | SKIN ANTI-AGEING COMPOSITION | LYMA Life Ltd. (GB) | 2026-04-08 | — | — | EP | claimed |
| EP-4713343-A2 | ENZYMATICALLY ACTIVE DOMAINS FROM ANTI-STAPHYLOCOCCAL PHAGE PROTEINS | Topaz Biosciences, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3402574-B1 | PERSONAL CARE COMPOSITIONS | COLGATE PALMOLIVE CO (US) | 2026-02-04 | — | — | EP | claimed |
| US-20260021029-A1 | HAIR REPAIR AND PROTECTION | OLAPLEX INC (US) | 2026-01-22 | — | — | US | claimed |
| US-20260007726-A1 | RECOMBINANT CELL WALL HYDROLASES | TOPAZ BIOSCIENCES INC (US) | 2026-01-08 | — | — | US | claimed |
| US-12496266-B2 | Skin care product with protein matrix | Eighth Day Labs, LLC (US) | 2025-12-16 | — | — | US | claimed |
| US-4737360-A | POLLEN EXTRACT AND VEGETABLE OILS | CERNITIN AMERICA, INC. (US) | 1988-04-12 | — | — | US | claimed |
| US-4690774-A | HUMECTANT, PETROLEUM JELLY AND EMULSIFIERS | CHESEBROUGH POND'S INC. (US) | 1987-09-01 | — | — | US | claimed |
| EP-0087374-B1 | ALLANTOIN-HYDROLYZED ANIMAL PROTEIN PRODUCT | CHARLES OF THE RITZ GROUP LTD. (US) | 1987-05-27 | — | — | EP | claimed |
| EP-0216557-A2 | Translucent water-in-oil emulsions | CHESEBROUGH-POND'S INC. (US) | 1987-04-01 | — | — | EP | claimed |
| EP-0203750-A2 | Ultra mild skin cleansing composition | THE PROCTER & GAMBLE COMPANY (US) | 1986-12-03 | — | — | EP | claimed |
| EP-0194097-A1 | Mild cleansing mousse | THE PROCTER & GAMBLE COMPANY (US) | 1986-09-10 | — | — | EP | claimed |
| US-4482537-A | COSMETICS, TOILETRIES | CHARLES OF THE RITZ GROUP LTD. (US) | 1984-11-13 | — | — | US | claimed |
| US-4481186-A | SKIN CONDITIONERS | CHARLES OF THE RITZ GROUP LTD. (US) | 1984-11-06 | — | — | US | claimed |
| US-4416873-A | CONTAINS PANTHENOL, UREA, ETHANOL, AND ISOPROPANOL | CHARLES OF THE RITZ GROUP LTD. (US) | 1983-11-22 | — | — | US | claimed |
| EP-0087374-A2 | Allantoin-hydrolyzed animal protein product | CHARLES OF THE RITZ GROUP LTD. (US) | 1983-08-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021029-A1 | HAIR REPAIR AND PROTECTION | CROCC, YWHAZ, AAAS | BRD4 3757/4885BRD2 1916/4885LMNA 571/4885 |
| US-20260007726-A1 | RECOMBINANT CELL WALL HYDROLASES | CMBL, CUTA, ABHD11 | BRD4 2911/4885BRD2 2068/4885LMNA 3821/4885 |
| US-12605328-B2 | Cosmetic compositions and methods | CUTA, PRPH, SMURF2 | BRD4 3360/4885BRD2 2158/4885LMNA 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.